A Colombian study (48) and a Peruvian study (49), using a commercial ELISA kit, reported a prevalence of auto-Abs against IFN-α in individuals with severe COVID-19, at 16.7% and 48.2%, respectively. This evidence concerns the gene IFNA2 and COVID-19.